I. Benjamin Gaddie, OD, FAAO, summarized the best forms of treating and managing demodex blepharitis.

Generated fourth quarter and full-year 2024 net product sales of XDEMVY® of $66.4 million and $180.1 million, respectively, ...

of a kind specifically known as Demodex blepharitis (an inflammation of the eyelid from the face mites) and skin issues like itchiness and flaking. Those are especially common among people with ...

Colorado Springs, Colorado - Colorado Springs, CO — Colorado Springs Eyecare is excited to announce the addition of ZEST ...

The initial patient response from this campaign has been positive across multiple leading indicators, including the downloading of materials, taking the Demodex blepharitis (DB) quiz and utilizing ...

Generated fourth quarter and full-year 2024 net product sales of XDEMVY ® of $66.4 million and $180.1 million, respectively, during the first full year of launch Presented groundbreaking XDEMVY data; ...

Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as ...

"We believe we are only beginning to unlock our full potential as the next leader in eye care and have so much to look forward to, including, potentially serving the millions of patients impacted by ...